Rep. Gilbert Cisneros (D-CA) Buys Shares of Arcutis Biotherapeutics, Inc. $ARQT
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
- Party:
- democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. ($ARQT) | Buy | May 29, 2026 | $1,001 - $15,000 |
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Gilbert Cisneros, a democrat member of the House, bought $1,001 - $15,000 of Arcutis Biotherapeutics, Inc. ($ARQT) stock on 2026-05-29, according to a periodic transaction report filed under the STOCK Act. Disclosures are filed after the trade and reflect a dollar range, not an exact amount.
Gilbert Cisneros vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Arcutis Biotherapeutics, Inc. Stock Up 10.5%
Shares of Arcutis Biotherapeutics, Inc. ($ARQT) traded around $26.28 on Saturday, up 10.5% for the day.
Arcutis Biotherapeutics, Inc. Earnings
Analysts Set New Price Targets
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Get Arcutis Biotherapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ARQT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.